Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 10, Issue 11
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
PDF +
Supplementary
Material
Clinical/translational cancer immunotherapy
Original research
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Online download statistics by month:
Online download statistics by month: November 2022 to February 2024
Abstract
Full
Pdf
Nov 2022
60
60
13
Dec 2022
535
539
226
Jan 2023
434
434
51
Feb 2023
143
143
43
Mar 2023
94
95
44
Apr 2023
73
73
41
May 2023
72
73
36
Jun 2023
60
60
21
Jul 2023
42
42
25
Aug 2023
66
66
32
Sep 2023
64
64
25
Oct 2023
82
83
46
Nov 2023
85
85
33
Dec 2023
72
72
35
Jan 2024
73
74
63
Feb 2024
93
93
33
Total
2048
2056
767
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?